KREBS BIOCHEMICALS & INDUSTRIES LTD.-$ Q4 FY26 Results

Summary

Krebs Biochemicals & Industries Limited reported a mixed financial performance for the year ended March 31, 2026. While the full-year revenue from operations experienced a significant decline of 45.2% to ₹2,373.16 lacs, the company managed to reduce its annual loss by 37.1%, reporting a loss of (₹1,693.31) lacs for FY26. The fourth quarter showed some signs of improvement, with revenue increasing by 11.6% year-on-year to ₹680.91 lacs and the quarterly loss narrowing substantially by 71.7% to (₹233.96) lacs compared to Q4FY25. However, the company's operations continued to be impacted by the ongoing closure of its Vizag manufacturing unit due to a pollution control board order.

Key Highlights

1. 1

   Revenue from operations for Q4FY26 increased by 11.6% year-on-year to ₹680.91 lacs.

2. 2

   The company significantly reduced its loss for Q4FY26, with Profit/(Loss) for the period at (₹233.96) lacs, a 71.7% reduction compared to the (₹826.84) lacs loss in Q4FY25.

3. 3

   For the full financial year ended March 31, 2026, Revenue from Operations declined by 45.2% to ₹2,373.16 lacs.

4. 4

   The annual Profit/(Loss) for FY26 showed an improvement, with a loss of (₹1,693.31) lacs, representing a 37.1% reduction from the (₹2,693.93) lacs loss reported in FY25.

5. 5

   Basic Earnings Per Share for Q4FY26 improved to (₹1.09) per share from (₹3.83) per share in the corresponding quarter of the previous year.

6. 6

   The company's Vizag manufacturing unit remained closed throughout the period due to an order from the Andhra Pradesh Pollution Control Board, impacting operations.

7. 7

   The Board of Directors approved the audited financial results for Q4 and FY26, accompanied by an unmodified audit report.